For those who do not meet DAPT clinical criteria, SAPT is recommended. The PRoFESS trial found no dif- ference in secondary stroke prevention after noncardioembolic stroke for aspirin-dipyridamole The ESPRIT trial (European/ Australasian Stroke Prevention in Reversible suggested that aspirin-dipyri- damole may be slightly more effective than aspi- rin alone for vascular event prevention, as did the ESPS2 trial (Second European Stroke Prevention ESPS2 also showed that aspirin alone is more effective than placebo in reducing recur- rent stroke. The CAPRIE trial (Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events) was not focused strictly on secondary prevention but found fewer events among patients treated with clopidogrel compared with those treated with aspirin, although no benefit was seen in stroke reduction among the stroke subgroup. A pooled analysis of trials in patients with lacunar stroke suggested that any of the evaluated antiplatelet agents were similarly effective compared with pla- Aspirin dosing may be guided by a recent patient-level pooled analysis of data from primary prevention RCTs that showed weight-based dos- ing (eg, aspirin 75 100 mg for patients weighing <70 kg and higher doses for those >70 kg) is more effective for the prevention of vascular events.803 However, similar studies have not been performed for secondary stroke prevention. 3. Recommendations for the short-term (21 90 days) use of DAPT with aspirin and clopidogrel are informed by 2 major RCTs,384,410 and a systematic review by an AHA Evidence Review Committee.15 Both the CHANCE and POINT trials compared DAPT with SAPT with aspirin initiated early after onset (<24 and <12 hours, respectively) of minor stroke (NIHSS score 3) or high-risk TIA (ABCD2 score 4) but varied in duration of DAPT treatment (21 and 90 days, respectively). 